| Prev Close | 192.99 |
| Open | 193.01 |
| Day Low/High | 191.64 / 193.38 |
| 52 Wk Low/High | 114.27 / 202.22 |
| Volume | 12.44M |
Allergan plc (AGN)
193.02
0.03
0.02
NYSE
| Exchange | NYSE |
| Div & Yield | N.A. (N.A) |
Two Antibiotic Plays
They may not get all the attention, but antibiotic drugs are increasingly important.
Passing on Allergan
Over the last few weeks I have received numerous requests to update my view on Allergan . I spent about an hour going over my research file on the company last night and I still can not see any upside catalysts. So I will continue to pass on the nam...
Surveying the M&A Landscape in Biotech
Who might be in play in the quarters ahead?
Jim Cramer: Markets Expect Too Much from Under Armour, IBM and These Other Names
The stocks inexplicably fell even after they delivered good earnings.
Allergan Is Still In a Downtrend as We Wait for a Bottom to Form
Allergan's bottom is going to take more time.
Video: Jim Cramer on T-Mobile, Sprint, AT&T, Centene and Allergan
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending stocks from the floor of the New York Stock Exchange.
Subscriber Comment of the Day
MFrank • a minute ago Why I think is down after a beat, CEO comment: NEW YORK (Reuters) - Allergan Plc (AGN.N) Chief Executive Brent Saunders said on Monday that while the company is considering large, transformational deals as part of a strategic r...
Break in!
Allergan is considering a split up of the company.
Here's My Take on Biotech Stocks
I think M&A activity will pick up markedly going forward across the industry.
Some Biotech Stocks to Add Exposure To
Secondary offerings create buying opportunities.
Revance Therapeutics Stock Looks Ready for New Gains
I don't understand the fundamentals but I find the chart interesting.
Allergan Hits New Low
Allergan hits a new low -- I would continue to avoid.
Subscriber Comment of the Day (Part Deux)
Subscriber Comment of the Day (Part Deux): Neil S Allergan's stock is probably seeing additional weakness from two announcements: Mylan's biosmilar Botox partnership with Revance and the Food and Drug Administration's extension of the PDUFA date for...
Avoid Allergan
There has been continued discussion in the Comments Section about whether Allergan should be purchased at today's levels. My answer remains no -- after spending time updating the company's fundamentals recently. I see no apparent upside catalyst and...
Revisiting Allergan
I got a bunch of emails from subscribers who asked me to update my view on Allergan -- after yesterday's large gain. I did some quick research for about thirty minutes this morning to update the shares and I remain of the view that I can't see any c...
Jim Cramer: Drug Stocks on the Move
We could be poised for even a further advance PROVIDED that we stay oversold.
Cramer: 10 Stock Surprises
In this tape, weakness may just be a sign of rest and better times to come.
A Regular Winning Trade Becomes Roadkill in Market Meltdown
Maybe inverse and/or leveraged positions are perverse in nature.
Cramer vs. Chaikin: You Can't Trade Allergan
TheStreet's Jim Cramer and Marc Chaikin, of Chaikin Analytics, spent an hour together at our offices talking all things markets. Listen to the whole conversation below. In the except above, they discuss Allergan and why you can't trade it.
8 Stocks That Are Ready to Change Direction
These names are displaying bullish and bearish reversal patters over the last week.
Allergan Needs More Time to Make a Proper Bottom
The charts suggest that Allergan isn't going to accelerate any time soon.
Jim Cramer: I Blame the Pajama Traders for This Selloff
They make more irrational, stupid moves based on nothing than I ever thought possible.
Subscriber Comment of the Day
Subscriber Comment of the day: Elihu Smails • 30 minutes ago Allergan to axe 1,000 jobs in order to hit 2018 income target By: Douglas W. House, SA News Editor Following through on its November 2017 announcement (Q3 earnings call on Nov. 1) that it ...
Some Morning Observations
So far: * Retail is quickly reversing yesterdays strength. Dillard's (-$1.70) and Macy's (-$0.70) downside leaders. * Gold quiet, +$1.90. Though optimistic for the full year I would not chase SPDY Gold ETF GLD at these levels. (I am a buyer on weakn...
Schlumberger Is a Stock to Watch in 2018
A promising and familiar pattern has developed in SLB. Here's how to play it.
Puke, Freeze or Add: Allergan
Last month I added a new occasional feature entitled "Puke, Freeze or Add?" -- Hat Tip Euro. My first column was on General Electric , in which my response was... "Freeze." Today I ask on Allergan , "Puke, Freeze or Add?" Allergan has now declined...
Wrap Up
I was out of the office most of the day. To me the most interesting asset class move was in bonds -- with yields down by over five basis points. The 10-year yield fell to under 2.35% though the 2s/10s curve was flat. While municipals rallied in pric...
Key Feature in Marketks
The key feature within the markets is the renewed and continued strength in pharma and biotech which started last week. Allergan , Celgene and Gilead Sciences are upside features. I am not involved and I would not chase big Pharma or biotech.